Skip to main content

Table 3 Clinical performance of the DNA methylation biomarkers SHOX2 and SEPT9 and cytology in ascites samples

From: Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites

Diagnostic method Patients Test result
All patients Cancer patients Non-cancer patients Positivity Specificity
Cytology 283 134 149 26 % (35/134) 100 % (149/149)
Cellular SHOX2 283 134 149 11 % (15/134) 99 % (148/149)
Cellular SEPT9 283 134 149 18 % (24/134) 98 % (146/149)
Cellular SHOX2 + SEPT9 283 134 149 24 % (32/134) 97 % (144/149)
Cytology + cellular SHOX2 + SEPT9 283 134 149 37 % (49/134) 97 % (144/149)
Cell-free SHOX2 162 81 81 16 % (13/81) 99 % (80/81)
Cell-free SEPT9 162 81 81 23 % (19/81) 99 % (80/81)
Cell-free SHOX2 + SEPT9 162 81 81 31 % (25/81) 98 % (79/81)
Cytology + cell-free SHOX2 + SEPT9 162 81 81 43 % (35/81) 98 % (79/81)
Cytology + cell-free SHOX2 + SEPT9 + cellular DNA SHOX2 + SEPT9 162 81 81 47 % (38/81) 95 % (77/81)
  1. Positivity rates and specificity of DNA methylation and cytological analyses and combinations, thereof